Pembrolizumab for anaplastic thyroid cancer: a case study
Marra Aghajani(Camden and Campbelltown Hospitals), Tara L. Roberts(Camden and Campbelltown Hospitals), Helen M. McGuire(The University of Sydney), Barbara Fazekas de St Groth, Paul de Souza(St. George Hospital), Victoria Bray, Navin Niles(Camden and Campbelltown Hospitals), Thomas C. Jeffries(Western Sydney University), Jawad Saab(Liverpool Hospital), K.I. Shahila Ismail(Camden and Campbelltown Hospitals), Adam Cooper(Liverpool Hospital)
Cited by 30
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507